Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint In Phase 3 Trial In Chronic Hepatitis C Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 2/3, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086).
Source: www.medicalnewstoday.comForest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results Of Phase III Study Of Milnacipran For The Management Of Fibromyalgia Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for the management of fibromyalgia.
Source: www.medicalnewstoday.comZevalin Consolidation In Patients With Complete Remission After Induction Therapy Results In Durable Remission Of More Than 67 Months Cell Therapeutics, Inc.
Source: www.medicalnewstoday.comRib-X Pharmaceuticals Reports Positive Top-Line Results From Phase 2 Study Of Delafloxacin Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, announced positive topline results from a Phase 2 clinical trial with the intravenous form of its novel anionic quinolone antibiotic, delafloxacin (RX-3341).
Source: www.medicalnewstoday.comBeyond Seizure Control In The Treatment Of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate) Positive data from three phase III studies presented at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM
Source: www.medicalnewstoday.comDeCODE To Integrate New Genetic Risk Factor For Type 2 Diabetes Into Its DeCODEme(TM) Personal Genome Scan Service deCODE genetics (Nasdaq: DCGN) announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D).
Source: www.medicalnewstoday.comNew Phase II Data Show Safety Of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable To Warfarin Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of DU- 176b, an investigational oral Factor Xa inhibitor, experienced comparable safety and tolerability compared to those taking warfarin, according to new Phase II data presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco.
Source: www.medicalnewstoday.comMission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin Mission Pharmacal announced the addition of CitraNatal(R) Assure to its CitraNatal(R) family of
prescription prenatal vitamins. CitraNatal Assure builds on the benefits of the CitraNatal line and offers increased nutrients for women and their babies. Prenatal vitamins are an important resource for women who are pregnant or planning to become pregnant. They provide women with the essential vitamins and minerals they may be lacking from a
healthy diet alone.
Source: www.medicalnewstoday.comMedarex Announces Enhanced Activity Data With Second Generation Anti-CD30 Antibody For Malignant Lymphoma Medarex, Inc. (Nasdaq: MEDX) announced results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Hodgkin's lymphoma (HL) as well as other CD30-expressing cancers. MDX-1401 demonstrated almost a doubling in potency and efficacy in cell lines when compared to MDX-060.
Source: www.medicalnewstoday.comA Women's Sexual Pleasure And Satisfaction Shaped By Contraceptive Methods New data from The Kinsey Institute at Indiana University demonstrate that many women think condoms undermine sexual pleasure, but those who use both hormonal contraception and condoms report higher overall sexual satisfaction. The study authors suggest that this inconsistency reflects how women think about their contraceptive method when asked questions about two different aspects of sexuality - sexual enjoyment and overall sexual satisfaction.
Source: www.medicalnewstoday.com
# posted by Network @ 11:00 AM
